The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Bronte G, Franchina T, Alù M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A.
Bronte G, et al. Among authors: franchina t.
Oncotarget. 2016 Jun 14;7(24):35803-35812. doi: 10.18632/oncotarget.8130.
Oncotarget. 2016.
PMID: 26993607
Free PMC article.